GARP Marker for Treg Cell Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack specific markers to accurately identify and isolate human regulatory T cells (Treg cells), which are crucial for maintaining immune balance and controlling autoimmune responses, due to the non-specific expression of existing markers like CD25.
Innovation Solution
The use of glycoprotein A repetitions predominant (GARP), a leucine-rich repeat containing protein, as a marker to identify and isolate Treg cells through affinity ligands such as antibodies that bind specifically to GARP, facilitating their separation from other T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CD25 expression is used to identify Treg cells, then Treg cells can be identified as CD4+ T cells expressing high levels of CD25, but activated T cells also express CD25 making the marker non-specific
Solution Approach 1:
The patent segments the Treg cell identification process into multiple distinct markers: CD4, CD25, and GARP. By using GARP as an additional specific marker that is preferentially expressed on Treg cells compared to activated T cells, the methodology divides the identification task into complementary parts that together provide both sensitivity and specificity.
Solution Approach 2:
The patent applies local quality by introducing GARP as a marker with differentiated expression patterns - it is highly expressed on Treg cells but not on activated T cells. This creates a localized specificity property that distinguishes Treg cells from other CD25+ cells, allowing precise identification of the target cell population.
2Quantity of substance
If CD25high+ cells are selected as Treg cells, then a population representing 5-10% of CD4+ T cells is identified, but it remains unknown what percentage are actually regulatory T cells
Solution Approach 1:
The patent introduces GARP as an intermediary marker that mediates between the abundant but non-specific CD25 marker and the need for pure Treg cell isolation. GARP serves as a filtering intermediary that enriches the Treg cell population by excluding activated T cells that express CD25 but not GARP, thereby improving both purity and precision of identification.
3Measurement precision
If Foxp3 expression is used to differentiate Treg cells from activated T cells, then Treg cell identity can be validated, but Foxp3 is intracellularly expressed limiting utility for cell manipulation
Solution Approach 1:
The patent uses GARP as a surface copy or surrogate marker that mirrors the Treg cell identity function of intracellular Foxp3 but with the advantage of surface expression. GARP serves as a copy of the Treg cell signature that can be detected externally, enabling both validation and practical manipulation of Treg cells without requiring intracellular analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GARP expression allows for the effective identification and isolation of Treg cells, enabling their use in therapeutic applications to modulate immune responses and treat autoimmune diseases and malignancies by suppressing or enhancing effector T cell activity.
Implementation Method 1
an affinity ligand reactive with a GARP protein... An antibody specific for a region of the GARP protein detectable on the surface of intact cells
Data Source
AI summary
An affinity ligand is reactive to the GARP protein may be capable of binding to an extracellular domain of GARP protein expressed on regulatory T (Treg) cells. The affinity ligand may be an antibody and may be used to identify Treg cells. A method comprises providing a blood sample from a subject and determining the amount of Treg cells in that sample. A composition containing Treg cells may be administered to an individual to suppress effector T cell activity in the individual. A composition containing an affinity ligand capable of binding to a GARP domain may be administered to an individual to suppress Treg cell activity and increase effector T cell activity in the individual. A kit for detecting Treg cells may include an affinity ligand reactive with mammalian GARP protein.